Aktuellt
SENASTE
Redeye notes that Nanexa’s Q1 report offered no material surprises, with revenues at SEK7.8m and OPEX at SEK-17.6m. As previously communicated, the clinical trial application process in Germany has taken longer than expected and the company expects to start the trial by the end of Q2. The company’s cash (and equivalents) position amounted to SEK47.8m and the board assesses that the company’s cash position should last (at least) 12 months. We will participate in today’s call and the CMD on Tuesday and will after that return with a more extensive take on the report and the presented material.
LÄS MER
